<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Dopamine-receptor agonists: Parkinson’s disease; Pramipexole; Ropinirole; Rotigotine; Bromocriptine: Parkinson’s disease; Cabergoline: Parkinson’s disease; Pergolide; Apomorphine" /><meta name="IX" content="Dopamine-receptor agonists: Parkinson’s disease; Pramipexole; Ropinirole; Rotigotine; Bromocriptine: Parkinson’s disease; Cabergoline: Parkinson’s disease; Pergolide; Apomorphine" /><title>Dopamine-receptor agonists: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="129827.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="129827.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=129827.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2055.htm">4 Central nervous system</a> &gt; <a href="3631.htm">4.9 Drugs used in parkinsonism and related disorders</a> &gt; <a href="3632.htm">4.9.1 Dopaminergic drugs used in Parkinson’s disease</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="3632.htm" title="Previous: 4.9.1 Dopaminergic drugs used in Parkinson’s disease">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="10071.htm" title="Next: APOMORPHINE HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_129827">Dopamine-receptor agonists</h1><?highlighter on?><div id="pC" class="jN"><div><p>The dopamine-receptor agonists
have a direct action on dopamine receptors. Initial treatment of Parkinson’s
disease is often with the dopamine-receptor agonists <b>pramipexole</b>, <span><b>ropinirole</b></span>, and <b>rotigotine</b>. The ergot-derived dopamine-receptor
agonists <span><b>bromocriptine</b></span>, <span><b>cabergoline</b></span>,  and <span><b>pergolide</b></span> are rarely used because the
risk of fibrotic reactions (see <a title="BNF:target-block: Fibrotic reactions" href="129827.htm#_3632.1">notes below</a>).</p><p>When used alone, dopamine-receptor agonists cause fewer motor
complications in long-term treatment compared with <span>levodopa</span> treatment but the overall motor performance improves slightly less.
The dopamine-receptor agonists are associated with more psychiatric
side-effects than <span>levodopa</span>.</p><p>Dopamine-receptor agonists are also used with <span>levodopa</span> in more advanced disease. If a dopamine-receptor agonist is added
to levodopa therapy, the dose of levodopa needs to be reduced (see
individual monographs).</p><div class="cN"><h3 class="cBP">Impulse control disorders</h3><p>Treatment with dopamine-receptor agonists and levodopa is associated
with impulse control disorders, including pathological gambling, binge
eating, and hypersexuality. <span id="_211435">Patients and
their carers should be informed about the risk of impulse control
disorders. There is no evidence that ergot- and non-ergot-derived
dopamine-receptor agonists differ in their propensity to cause impulse
control disorders, so switching between dopamine-receptor agonists
to control these side-effects is not recommended. If
the patient develops an impulse control disorder, the dopamine-receptor
agonist or levodopa should be withdrawn or the dose reduced until
the symptoms resolve.</span></p></div><div id="_214348"><p>Antiparkinsonian drug therapy should never be stopped
abruptly as this carries a small risk of neuroleptic malignant syndrome.</p></div><div id="_3632.1"><div class="cN"><h3 class="cBP">Fibrotic reactions</h3><p>Ergot-derived dopamine-receptor agonists, <span>bromocriptine</span>, <span>cabergoline</span>, and <span>pergolide</span>, have been associated with pulmonary, retroperitoneal, and pericardial
fibrotic reactions. </p><p>Exclude cardiac valvulopathy with echocardiography before starting
treatment with these ergot derivatives for Parkinson’s disease or
chronic endocrine disorders (excludes suppression of lactation); it
may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine
and to obtain a chest X-ray. Patients should be monitored
for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal
pain or tenderness. If long-term treatment
is expected, then lung-function tests may also be helpful. Patients taking cabergoline or pergolide should be
regularly monitored for cardiac fibrosis by echocardiography (within
3–6 months of initiating treatment and subsequently at 6–12 month
intervals).</p></div></div><div id="_213600"><div class="cN"><div class="cAZ"><h2>Driving</h2><div><h3 class="cAE">Sudden onset of sleep</h3> <p class="cAE">Excessive daytime sleepiness and sudden onset of sleep can occur
with <span>co-careldopa</span>, <span>co-beneldopa</span>, and dopamine-receptor agonists.</p><p>Patients starting treatment with these drugs should be warned of
the risk and of the need to exercise caution when driving or operating
machinery. Those who have experienced excessive sedation
or sudden onset of sleep should refrain from driving or operating
machines until these effects have stopped occurring.</p><p>Management of excessive daytime sleepiness should focus on the
identification of an underlying cause, such as depression or concomitant
medication. Patients should be counselled on improving sleep behaviour.</p></div><div><h3 class="cAE">Hypotensive reactions</h3> <p class="cAE">Hypotensive reactions can occur in some patients
taking dopamine-receptor agonists; these can be particularly
problematic during the first few days of treatment and care should
be exercised when driving or operating machinery.</p></div></div></div></div><div id="_213651"><p><span><b>Apomorphine</b></span> is a potent dopamine-receptor agonist
that is sometimes helpful in advanced disease for patients experiencing
unpredictable ‘off’ periods with <span>levodopa</span> treatment. <span>Apomorphine</span> should be initiated in a specialist clinic
with at least two days pretreatment with <a title="BNF:monograph: DOMPERIDONE" href="3429.htm#_3429">domperidone</a> for nausea and vomiting. After an overnight
withdrawal of oral antiparkinsonian medication to induce an ‘off’
episode, the threshold dose of apomorphine is determined. Oral antiparkinsonian
medication is then restarted. The patient must be taught to self-administer <span>apomorphine</span> by subcutaneous injection into the lower abdomen
or outer thigh at the first sign of an ‘off’ episode. Once treatment
has been established it may be possible to gradually reduce other
antiparkinsonian medications and reduce or withdraw <span>domperidone</span> therapy. Treatment with <span>apomorphine</span> should remain
under specialist supervision.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_10071"><a href="10071.htm" title="APOMORPHINE HYDROCHLORIDE">APOMORPHINE HYDROCHLORIDE</a></li><li id="_3646"><a href="3646.htm" title="BROMOCRIPTINE">BROMOCRIPTINE</a></li><li id="_128145"><a href="128145.htm" title="CABERGOLINE">CABERGOLINE</a></li><li id="_3650"><a href="3650.htm" title="PERGOLIDE">PERGOLIDE</a></li><li id="_77550"><a href="77550.htm" title="PRAMIPEXOLE">PRAMIPEXOLE</a></li><li id="_57171"><a href="57171.htm" title="ROPINIROLE">ROPINIROLE</a></li><li id="_129661"><a href="129661.htm" title="ROTIGOTINE">ROTIGOTINE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="3632.htm">Previous: 4.9.1 Dopaminergic drugs used in Parkinson’s disease</a> | <a class="top" href="129827.htm#">Top</a> | <a accesskey="]" href="10071.htm">Next: APOMORPHINE HYDROCHLORIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>